Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

XORTX Appoints Chairman

  • May 8, 2018December 22, 2020
  • by aaronbb

CALGARY, Alberta, May 08, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Bruce Rowlands, a director of XORTX as Chairman of the Board of Directors.

 » See full original release

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Google+ (Opens in new window)

Related

XORTX Announces PKD Foundation Collaboration
XORTX to Commence Trading on the OTCQB Venture Market

Press Releases

  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
  • XORTX Participating in WuXI Healthcare Forum March 1, 2021
  • XORTX to Present at BIO CEO and Investor Conference February 17, 2021
  • XORTX Closes Over Subscribed Private Placement February 10, 2021
  • XORTX Announces Over Subscribed Private Placement February 8, 2021

Archives

  • 2012 Press Releases 3
  • 2014 Press Releases 2
  • 2015 Press Releases 1
  • 2017 Press Releases 2
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress